Miriam Bergeret is a science writer and editor based in Toronto, Canada. Miriam holds a master's degree in laboratory medicine and pathobiology from the University of Toronto, where she also studied science journalism and communication.
In an extremely rare case, a patient who received a cell-based cancer treatment later developed a second cancer that arose from the treatment itself.
Despite the low risk, these sporadic cases have drawn scrutiny from the FDA and left the research community with unanswered questions about the underlying causes and potential risk of CAR-related secondary cancers. The FDA maintains that the overall benefit of these therapies outweighs potential risks, but the agency wants to better understand the risks, nonetheless.
By submitting your information you agree to the Terms & Conditions and Privacy Policy and are aged 16 or over.The tumor was CAR-positive, indicating that the cancer had arisen from one of the immune cells modified for the woman's treatment.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Troy catcher Brooks Bryan named first-team All-Sun Belt ConferenceTrojans place 5 on 2nd team; South Alabama’s Grant Wood also makes 2nd team
Read more »
Six-Year NBA Veteran Reportedly Joins New TeamThis NBA veteran played for the Memphis Grizzlies, Toronto Raptors, Brooklyn Nets, and Toronto Raptors
Read more »
This time, it's personal: Enhancing patient response to cancer immunotherapyScientists uncover why cancer patients with ARID1A gene mutations are more likely to respond to immunotherapy, discovering ARID1A mutations invite cancer-fighting immune cells into tumors by triggering an antiviral-like response.
Read more »
Circadian clock can be leveraged to enhance cancer immunotherapyA multidisciplinary research team has revealed that the circadian clock -- the biological pacemaker that governs daily rhythms in physiological processes, including immune functions -- can be leveraged to enhance the efficacy of checkpoint inhibitor cancer therapy.
Read more »
Research finds VISTA directly blocks T-cells from functioning in immunotherapyA team of scientists and physicians have discovered that the immune checkpoint protein VISTA can directly turn off tumor-fighting T-cells during immunotherapy and resist treatment. The study explains that VISTA can bind to a protein called LRIG1 in T cells, which was previously only thought to promote bone and fat development.
Read more »
Immunotherapy Before and After Surgery Boosts Lung Cancer SurvivalImmunotherapy can boost the survival of early-stage lung cancer patients eligible for surgery when it’s combined with chemotherapy, a new clinical trial reports.
Read more »